Lars Fruergaard Jørgensen, Novo Nordisk CEO (Christopher Goodney/Bloomberg via Getty Images)

Four burn­ing ques­tions about the fu­ture of the $16.5B No­vo-Catal­ent deal

To build or to buy? That’s a clas­sic ques­tion for phar­ma board­rooms, and No­vo Nordisk is go­ing with both.

Be­yond spend­ing bil­lions of dol­lars to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.